Stroke RSS Page 2

Filtered By:
Source: American Heart Journal
Procedure: Coronary Artery Bypass Graft

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 36 results found since Jan 2013.

Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: pooled analysis from the EUROMAX and HORIZONS-AMI trials
Conclusions In a large group of elderly patients enrolled in the EUROMAX and HORIZONS-AMI trials, bivalirudin was associated with lower 30-day rates of non-CABG major bleeding, subacute ST and NACE, with similar 30-day rates of acute ST and mortality.
Source: American Heart Journal - August 18, 2017 Category: Cardiology Source Type: research

Preoperative factors associated with worsening in health-related quality of life following coronary artery bypass grafting in the ROOBY trial
Conclusions Among VA patients, less than 20% experienced worse HRQL 1year after CABG. For patients with low symptom burden at baseline, diabetes, smoking, depression, PVD, COPD, and a prior stroke, clinicians should be more cautious in pre-CABG counseling as to their anticipated HRQL improvements.
Source: American Heart Journal - December 25, 2017 Category: Cardiology Source Type: research

Outcome and safety of same-day-discharge percutaneous coronary interventions with femoral access: A single-center experience
Conclusions: Same-day-discharge after uncomplicated PCI using femoral access is safe when patients are properly selected. The strategy may improve and benefit health costs in the future.
Source: American Heart Journal - January 28, 2013 Category: Cardiology Authors: Lisbeth Antonsen, Lisette Okkels Jensen, Per Thayssen Tags: Interventional Cardiology Source Type: research

Treatment of functional mitral valve regurgitation with the permanent percutaneous transvenous mitral annuloplasty system: Results of the multicenter international Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients with Heart Failure trial
Conclusions: Overall, PTMA had mild impact on MR reduction, left ventricular remodeling, QOL, and exercise capacity. During follow-up, the risk/benefit ratio remained suboptimal.
Source: American Heart Journal - February 18, 2013 Category: Cardiology Authors: Jimmy MacHaalany, Luc Bilodeau, Rainer Hoffmann, Stefan Sack, Horst Sievert, Josef Kautzner, Christoph Hehrlein, Patrick Serruys, Mario Sénéchal, Pamela Douglas, Olivier F. Bertrand Tags: Valvular and Congenital Heart Disease Source Type: research

Atrial fibrillation among Medicare beneficiaries hospitalized with sepsis: Incidence and risk factors
Background: Newly diagnosed atrial fibrillation (AF) during severe sepsis is associated with increased risks of in-hospital stroke and mortality. However, the prevalence, incidence, and risk factors associated with AF during the sepsis syndromes are unclear.Methods: We identified patients with preexisting, newly diagnosed, or no AF in a nationally representative 5% sample of Medicare beneficiaries hospitalized with sepsis between 2004 and 2007. We identified multivariable-adjusted demographic and clinical characteristics associated with development of newly diagnosed AF during a sepsis hospitalization.Results: A total of 6...
Source: American Heart Journal - April 26, 2013 Category: Cardiology Authors: Allan J. Walkey, Melissa A. Greiner, Susan R. Heckbert, Paul N. Jensen, Jonathan P. Piccini, Moritz F. Sinner, Lesley H. Curtis, Emelia J. Benjamin Tags: Electrophysiology Source Type: research

Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: Insights from the PLATelet inhibition and patient outcomes (PLATO) trial
Conclusions: Prior-CABG patients presenting with acute coronary syndrome are a high-risk cohort for death and recurrent cardiovascular events but have a lower risk for major bleeding. Similar to the results in no-prior-CABG patients, ticagrelor was associated with a reduction in ischemic events without an increase in major bleeding.
Source: American Heart Journal - July 29, 2013 Category: Cardiology Authors: Emmanouil S. Brilakis, Claes Held, Bernhard Meier, Frank Cools, Marc J. Claeys, Jan H. Cornel, Philip Aylward, Basil S. Lewis, Douglas Weaver, Gunnar Brandrup-Wognsen, Susanna R. Stevens, Anders Himmelmann, Lars Wallentin, Stefan K. James Tags: Acute Ischemic Heart Disease Source Type: research

The need to know crude event rates in meta-analysis
Numerous reports have recently been aimed at comparing outcomes between on-pump and off-pump coronary artery bypass grafting (CABG). Among these, the meta-analysis by Palmerini et al compared percutaneous coronary intervention with CABG using a network design that included 1 patient group receiving percutaneous coronary intervention (n = 4,653) and 2 patient groups in whom CABG was performed either on-pump (n = 10,957) or off-pump (n = 7,119). The rate of stroke at 30 days was the main end point.
Source: American Heart Journal - July 26, 2013 Category: Cardiology Authors: Andrea Messori, Valeria Fadda, Dario Maratea, Sabrina Trippoli Tags: Letters to the Editor Source Type: research

Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
Background: Extensive coronary artery disease (CAD) is associated with higher risk. In this substudy of the PLATO trial, we examined the effects of randomized treatment on outcome events and safety in relation to the extent of CAD.Methods: Patients were classified according to presence of extensive CAD (defined as 3-vessel disease, left main disease, or prior coronary artery bypass graft surgery). The trial's primary and secondary end points were compared using Cox proportional hazards regression.Results: Among 15,388 study patients for whom the extent of CAD was known, 4,646 (30%) had extensive CAD. Patients with extensiv...
Source: American Heart Journal - April 14, 2014 Category: Cardiology Authors: Anna Kotsia, Emmanouil S. Brilakis, Claes Held, Christopher Cannon, Gabriel P. Steg, Bernhard Meier, Frank Cools, Marc J. Claeys, Jan H. Cornel, Philip Aylward, Basil S. Lewis, Douglas Weaver, Gunnar Brandrup-Wognsen, Susanna R. Stevens, Anders Himmelmann Tags: Acute Ischemic Heart Disease Source Type: research

Off-hour admission and outcomes for patients with acute myocardial infarction undergoing percutaneous coronary interventions
Conclusions Patients who were admitted during off-hours did not have higher mortality or readmission rates as compared with ones admitted during regular hours at an academic medical center.
Source: American Heart Journal - December 9, 2014 Category: Cardiology Source Type: research

Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Conclusions We observed consistency of effects in Asian patients receiving ticagrelor and clopidogrel in the PLATO study. The relatively modest number of Asian patients in this analysis supports further investigation of larger cohorts to confirm our observations.
Source: American Heart Journal - April 3, 2015 Category: Cardiology Source Type: research

Radial versus Femoral Access for Elderly Patients with Acute Coronary Syndrome undergoing Coronary Angiography and Intervention: Insights from the RIVAL Trial
Conclusions Consistent with the overall RIVAL trial population, elderly patients undergoing cardiac catheterization have lower rates of major bleeding or access site complications and higher rates of access site crossover with radial access compared to femoral access.
Source: American Heart Journal - August 16, 2015 Category: Cardiology Source Type: research

A Randomized, Parallel Group, Double-Blind Study of Ticagrelor compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation: Rationale and Design of the Ticagrelor in CABG (TiCAB-) Trial
Publication date: Available online 18 June 2016 Source:American Heart Journal Author(s): Antoinette de Waha, Sigrid Sandner, Moritz von Scheidt, Andreas Boening, Katharina Koch-Buettner, Dieter Hammel, Rainer Hambrecht, Bernhard C. Danner, Friedrich A. Schöndube, Gerold Goerlach, Theodor Fischlein, Michael Schmoeckel, Martin Oberhoffer, Rainer Schulz, Thomas Walther, Tibor Ziegelhöffer, Christoph Knosalla, Felix Schönrath, Friedhelm Beyersdorf, Matthias Siepe, Tim Attmann, Martin Misfeld, Friedrich-Wilhelm Mohr, Hans-Hinrich Sievers, Alexander Joost, Leon M. Putman, Günther Laufer, Christia...
Source: American Heart Journal - June 17, 2016 Category: Cardiology Source Type: research

Cangrelor reduces the risk of ischemic complications in patients with single and multi-vessel disease undergoing PCI: insights from the CHAMPION PHOENIX Trial
Conclusion In the CHAMPION-PHOENIX trial, MVD and SVD patients had similar ischemic outcomes at 48hours and 30days. Cangrelor consistently reduced ischemic complications in both SVD and MVD patients without a significant increase in GUSTO severe bleeding. Clinical Perspectives. What's known? Cangrelor is a novel, intravenous, potent, and rapidly-acting P2Y12 inhibitor, that has been demonstrated to reduce the rate of ischemic events at 48hours in patients who received PCI compared with clopidogrel. What's new? In contrast to prior studies, we found that in this modern cohort, patients with SVD and MVD had a similar risk of...
Source: American Heart Journal - March 9, 2017 Category: Cardiology Source Type: research

Pages: 1 2 3